Masaru Kanekiyo
A5052951174- Influenza Virus Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Viral gastroenteritis research and epidemiology
- HIV Research and Treatment
- vaccines and immunoinformatics approaches
- Immune Response and Inflammation
- Animal Virus Infections Studies
- Viral Infections and Outbreaks Research
- T-cell and B-cell Immunology
- Virus-based gene therapy research
- Herpesvirus Infections and Treatments
- Bacteriophages and microbial interactions
- RNA and protein synthesis mechanisms
- interferon and immune responses
- Diabetes and associated disorders
- Viral Infections and Immunology Research
- Viral-associated cancers and disorders
- Cytomegalovirus and herpesvirus research
- Complement system in diseases
- Protein Structure and Dynamics
- Glycosylation and Glycoproteins Research
National Institute of Allergy and Infectious Diseases
2016-2025
National Institutes of Health
2016-2025
Government of the United States of America
2023
Institut de Recherche Vaccinale
2023
Infectious Disease Research Institute
2008-2010
National Institute of Infectious Diseases
2005-2010
Iwate Medical University
2006
Osaka City University
2006
Ministry of Defense
2006
Nagasaki University
2006
Antibodies block Ebola virus entry The recent outbreak in West Africa illustrates the need for both an effective vaccine and therapies to treat infected individuals. Corti et al. isolated two monoclonal antibodies from a survivor of 1995 Kikwit demonstrated their therapeutic efficacy virus–infected macaques. In fact, one antibody protected macaques when it was given up 5 days after infection. Misasi solved crystal structures fragments bound glycoprotein (GP), which mediates viral cell entry....
Antibodies to the prefusion conformation of RSV F glycoprotein neutralize natural infection.
Abstract The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) as a cause severe disease highlights the need for effective approaches to CoV vaccine development. Efforts focused solely on receptor-binding domain (RBD) viral Spike (S) glycoprotein may not optimize neutralizing antibody (NAb) responses. Here we show that immunogens based full-length S DNA and S1 subunit protein elicit robust serum-neutralizing activity against several MERS-CoV strains in mice non-human...
An understanding of the antigen-specific B-cell response to influenza virus hemagglutinin (HA) is critical development universal vaccines, but it has not been possible examine these cells directly because HA binds sialic acid (SA) on most cell types. Here, we use structure-based modification isolate HA-specific B by flow cytometry and characterize features stem antibodies (Abs) required for their development. Incorporation a previously described mutation (Y98F) receptor binding site (RBS)...
Antibodies block Ebola virus entry The recent outbreak in West Africa illustrates the need for both an effective vaccine and therapies to treat infected individuals. Corti et al. isolated two monoclonal antibodies from a survivor of 1995 Kikwit demonstrated their therapeutic efficacy virus–infected macaques. In fact, one antibody protected macaques when it was given up 5 days after infection. Misasi solved crystal structures fragments bound glycoprotein (GP), which mediates viral cell entry....
ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) causes a highly lethal pulmonary infection with ∼35% mortality. The potential for future pandemic originating from animal reservoirs or health care-associated events is major public concern. There are no vaccines therapeutic agents currently available MERS-CoV. Using probe-based single B cell cloning strategy, we have identified and characterized multiple neutralizing monoclonal antibodies (MAbs) specifically binding to the...
Multivalent presentation of viral glycoproteins can substantially increase the elicitation antigen-specific antibodies. To enable a new generation anti-viral vaccines, we designed self-assembling protein nanoparticles with geometries tailored to present ectodomains influenza, HIV, and RSV glycoprotein trimers. We first de novo trimers for antigen fusion, featuring N-terminal helices positioned match C termini glycoproteins. Trimers that experimentally adopted their configurations were...
Current yearly seasonal influenza vaccines primarily induce an antibody response directed against the immunodominant but continually diversifying hemagglutinin (HA) head region. These responses provide protection vaccinating strain little cross-protection other strains or subtypes. To focus immune on subdominant more conserved epitopes HA stem that might protect a broad range of strains, we developed stabilized H1 immunogen lacking displayed ferritin nanoparticle (H1ssF). Here, evaluated B...
Influenza vaccines could be improved by platforms inducing cross-reactive immunity. Immunodominance of the influenza hemagglutinin (HA) head in currently licensed impedes induction neutralizing stem-directed antibodies. A vaccine without variable HA domain has potential to focus immune response on conserved stem. This first-in-human dose-escalation open-label phase 1 clinical trial (NCT03814720) tested an stabilized stem ferritin nanoparticle (H1ssF) based H1 A/New Caledonia/20/1999....
The lack of a licensed vaccine for respiratory syncytial virus (RSV) can be partly attributed to regulatory hurdles resulting from enhanced disease (ERD) subsequent natural RSV infection that was observed in clinical trials formalin-inactivated (FI-RSV) antigen-naïve infants. To develop an effective does not enhance illness, it is important understand how formalin and heat inactivation affected the antigenicity immunogenicity FI-RSV compared native virus. Informed by atomic structures fusion...
Current influenza vaccines are primarily strain specific, requiring annual updates, and offer minimal protection against drifted seasonal or pandemic strains. The highly conserved stem region of hemagglutinin (HA) group 2 A virus subtypes is a promising target for vaccine elicitation broad cross-group divergent We used structure-guided protein engineering employing multiple stabilization methods simultaneously to develop HA stem-based candidate immunogens displayed as trimers on...
Antigenic drift and shift of influenza strains underscore the need for broadly protective vaccines. One strategy is to design immunogens that elicit B cell responses against conserved epitopes on hemagglutinin (HA) stem. To better understand elicitation HA stem-targeted cells group 1 2 subtypes, we compared memory response H7N9 H5N1 vaccines in humans. Upon vaccination, almost half stem-specific recognized whereas was largely 1-specific. Immunoglobulin repertoire analysis HA-specific...
Abstract Because of significant viral diversity, vaccines that elicit durable and broad protection against influenza have been elusive. Recent research has focused on the potential highly conserved regions hemagglutinin (HA) as targets for broadly neutralizing Ab responses. Abs bind stem or stalk HA can be elicited by vaccination in humans animal models neutralize diverse strains. However, frequency phenotype stem–specific B cells vivo remain unclear. In this article, we characterize cell...